🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Cartesian Therapeutics, Inc. RNAC R2KPHARMA

Healthcare · Biotechnology · United States
https://www.cartesiantherapeutics.com
Company Profile ↓
$9.27
-20.84% 1Y
Mkt Cap$280.47M
P/E-1.60
P/B-1.71
52W High$11.71
52W Low$5.84
Book Value$-5.19
EPS (TTM)$-5.78

Company Overview

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 103.2%, reflecting efficient use of shareholder capital.

Recent Developments

  • Dec 2025 Revenue of $2.80M (-92.8% YoY); net profit $-130.30M.
  • Trailing 12 Months Year-on-year growth — revenue -92.8%, earnings -8.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR -0.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-0.83%
1 Year:-92.81%

Compounded Profit Growth

5 Years:-
1 Year:-8.00%

Stock Price Performance

1 Year:-20.84%
6 Months:+35.33%
3 Months:+58.73%
1 Month:+5.82%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 58% of range
$5.84 $11.71
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)50.53 · Neutral
Price Performance
1M+5.82%
3M+58.73%
6M+35.33%
1Y-20.84%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 103.2%.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -0.8% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.60
Industry PE
25.17
Forward P/E
-3.46
PEG Ratio
-
Book Value
$-5.19
Price to Book
-1.71
P/S
181.29
EV/EBITDA
-1.92
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-0.83%
Profit 5Y
-
Revenue (YoY)
-92.81%
Earnings (YoY)
-8.00%

Profitability & Returns

ROCE
-30.80%
ROE
103.22%
ROA
-17.43%
Profit Margin
0.00%
Op Margin
-
Gross Margin
0.00%
EPS (Latest Qtr)
$0.46
EPS (TTM)
$-5.78

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
7.19
Current Ratio
7.47
Debt
$63.85M
Total Assets
$318.63M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
52.13%
Chg in Prom Hold
-1.55%
FII / Inst Holding
29.45%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$280.47M
Total Revenue (TTM)
$1.48M
EBITDA
$-96.05M
Free Cash Flow
$-51.99M
Operating Cash Flow
$-76.53M
Shares Outstanding
30.26M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 RNAC Cartesian Therapeutics, Inc. R2KPHARMA 9.27 -1.60 $280.47M 0.00% -30.80% 103.22% -0.83% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue --------137.00K26.00K27.00K17.00K000903.00K10.00K13.00K06.65M004.65M11.05M19.66M24.43M34.00M39.27M20.71M5.94M5.25M6.55M5.84M33.27M0400.00K0000
Operating Income --6.32M-6.07M--6.94M-6.40M-7.47M--14.78M-15.87M-13.85M--15.81M-18.77M-15.94M--11.86M-16.23M-11.79M--18.82M-16.37M-13.73M-7.16M452.00K-1.97M10.77M13.86M-1.60M-18.38M-18.64M-13.06M-13.35M13.76M-17.57M-21.89M-21.81M-21.07M-26.50M-29.16M
Net Income -5.73M-6.87M-5.72M-6.85M-7.48M-6.92M-7.73M-14.08M-15.13M-15.97M-14.68M-19.54M-15.89M-18.80M-16.00M-14.65M-12.07M-16.39M-11.99M-14.89M-19.62M-24.08M-9.73M-24.60M4.57M-17.89M28.78M8.60M-7.89M-21.66M-11.39M-9.00M-56.82M13.84M-24.18M-17.71M15.89M-35.90M-39.18M15.77M
Diluted EPS ----------------------0.25-0.09-0.220.00-0.160.080.06-0.05-4.24-2.23-1.74-10.500.54-1.13-0.680.50-1.38-1.460.46
R&D Expense -5.31M5.48M-6.65M6.00M6.02M-11.04M10.99M9.50M-11.14M14.41M11.88M-7.35M12.13M8.10M-14.72M10.73M13.96M13.00M14.46M20.95M17.69M19.18M16.54M18.62M17.78M13.00M9.74M12.66M11.40M14.67M14.87M13.80M19.46M20.43M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 3.04M6.01M8.08M207.00K903.00K6.68M16.60M-110.78M26.00M38.91M2.80M
Cost of Revenue ------------
Gross Profit ------------
Operating Expenses --------96.24M111.71M75.23M89.50M
Operating Income -15.40M-25.30M-34.67M-63.78M-65.02M-52.45M-56.82M-14.54M-85.71M-36.32M-86.70M
EBITDA --------39.09M-235.03M-75.99M-83.75M
Interest Expense -------2.84M3.03M2.83M0-
Pretax Income --------34.77M-238.71M-77.14M-139.50M
Tax Provision ---------609.00K-19.00M287.00K-9.19M
Net Income -12.88M-25.17M-36.21M-65.32M-65.34M-55.35M-68.88M-35.38M-219.71M-77.42M-130.30M
Diluted EPS ------1.22-0.68-3.00-49.76-4.49-5.02
R&D Expense 10.49M22.98M29.70M45.16M47.69M42.74M54.51M68.74M72.38M71.26M45.10M58.03M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --42.82M89.30M101.10M101.10M44.48M99.57M165.44M159.88M165.89M305.05M435.02M296.41M
Total Equity -69.46M-87.75M-116.49M54.96M51.81M53.64M-5.42M8.40M-18.01M22.52M93.83M-440.18M-6.80M-126.24M
Cash & Equivalents 8.06M16.59M32.34M58.66M70.62M-37.40M89.89M138.69M114.06M106.44M76.91M212.61M125.14M
Total Liabilities --21.84M34.34M49.29M47.46M49.90M91.17M183.44M137.36M72.06M444.68M441.82M422.65M
Current Liabilities --7.29M13.71M10.97M10.97M35.14M34.94M81.55M72.25M25.08M68.21M22.98M14.94M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow --22.46M-19.76M-52.03M-59.16M-51.44M34.88M-60.38M-31.63M-51.16M-23.67M-73.94M
Investing Cash Flow --4.68M-22.10M-2.10M25.27M229.00K-741.00K-17.14M-15.00M34.61M-8.74M-5.45M
Financing Cash Flow -43.91M67.66M66.02M697.00K105.04M14.43M52.90M39.22M-13.14M168.43M-8.05M
Capital Expenditure -227.00K-1.16M-586.00K-733.00K-884.00K-47.00K-815.00K-1.08M-1.20M-206.00K-9.09M-5.45M
Free Cash Flow --23.63M-20.34M-52.76M-60.05M-51.48M34.07M-61.47M-32.83M-51.37M-32.77M-79.39M

Ratios (Annual)

Figures in %.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------------
Operating Margin % -506.5%-421.0%-428.9%-30,813.5%-7,200.7%-785.6%-342.4%-13.1%-329.6%-93.3%-3,099.9%
Net Margin % -423.7%-418.8%-448.0%-31,556.0%-7,235.4%-829.0%-415.0%-31.9%-844.9%-199.0%-4,658.6%
ROE % 14.7%21.6%-65.9%-126.1%1,205.9%-659.2%382.5%-37.7%49.9%1,138.3%103.2%
ROCE % --71.2%-45.9%-70.8%-696.3%-81.2%-67.7%-10.3%-36.2%-8.8%-30.8%

Shareholding Pattern

Insiders
52.13%
Institutions
29.45%
Public Float
61.53%

Top Institutional Holders

#Holder% HeldSharesValue
1 Squarepoint Ops LLC 7.45% 2.25M $21.64M
2 Blackrock Inc. 2.71% 819.24K $7.86M
3 683 Capital Management LLC 2.15% 650.00K $6.24M
4 Vanguard Capital Management LLC 1.84% 555.82K $5.34M
5 FMR, LLC 1.22% 368.43K $3.54M
6 Geode Capital Management, LLC 1.18% 356.52K $3.42M
7 AQR Capital Management, LLC 1.18% 356.46K $3.42M
8 Millennium Management Llc 1.02% 309.89K $2.97M
9 Two Sigma Investments, LP 0.98% 296.29K $2.84M
10 State Street Corporation 0.82% 249.21K $2.39M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RNAC

Yahoo Finance Fri, 07 Aug 2026

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of indu…

Yahoo Finance Fri, 12 Jun 2026

Cartesian Therapeutics Announces New Employment Inducement Grant

FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an i…

Yahoo Finance ue, 09 Jun 2026

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans to advance multiple Cartesian-owned, int…

Yahoo Finance ue, 26 May 2026

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028 Financing strengthens Cartesian’s financial flexibility, further supporting advancement o…

Yahoo Finance Sun, 17 May 2026

We're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo Finance ue, 12 May 2026

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management e…

RNAC — Frequently Asked Questions

What is the current share price of Cartesian Therapeutics, Inc. (RNAC)?

As of 2026-09-07 16:24 PDT, Cartesian Therapeutics, Inc. (RNAC) trades at $9.27 on NasdaqGM. Its 52-week range is $5.84 to $11.71.

What is the market capitalisation of RNAC?

Cartesian Therapeutics, Inc. (RNAC) has a market capitalisation of $280.47M on NasdaqGM.

What is the P/E ratio of RNAC?

RNAC trades at a trailing price-to-earnings (P/E) ratio of -1.60. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -1.71.

What is the return on equity (ROE) of RNAC?

RNAC has a return on equity (ROE) of 103.22%. Its return on capital employed (ROCE) is -30.80%.

Is RNAC a good stock to buy?

This page provides a data-driven analysis of Cartesian Therapeutics, Inc. (RNAC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space